Payment overview · 2025
General Payments
$395.61
18 reported records · 8 companies
Healthcare provider profile · identity verified
Tracey D Beverley, MD
Allopathic & Osteopathic Physicians|Family Medicine · MADISONVILLE, TN · NPI 1083651533
Verified facts
What the public records show
CMS Open Payments records show Tracey D Beverley, MD received $395.61 in general payments during 2025 across 18 reported records.
ViiV Healthcare Company accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $92.96 | 23.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.39 | 20.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.25 | 13.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.08 | 12.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.41 | 12.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.96 | 7.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.75 | 5.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.81 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.61 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.25 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $51.08 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.41 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.96 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 961 | 84 |
| Eliquis | Apixaban | 802 | 44 |
| Furosemide | Furosemide | 457 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 87 |
| Lisinopril | Lisinopril | 339 | 62 |
| Potassium Chloride | Potassium Chloride | 329 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 44 |
| Buspirone Hcl | Buspirone Hcl | 304 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 60 |
| Omeprazole | Omeprazole | 252 | 64 |
| Gabapentin | Gabapentin | 246 | 47 |
| Sertraline Hcl | Sertraline Hcl | 240 | 38 |
| Alprazolam | Alprazolam | 233 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 46 |
| Trazodone Hcl | Trazodone Hcl | 226 | 41 |
| Carvedilol | Carvedilol | 221 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 220 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 200 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 46 |
| Losartan Potassium | Losartan Potassium | 186 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 36 |
| Metformin Hcl | Metformin Hcl | 181 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 46 |
| Ondansetron Hcl | Ondansetron Hcl | 147 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 25 |
| Donepezil Hcl | Donepezil Hcl | 124 | 22 |
| Meloxicam | Meloxicam | 121 | 26 |
| Mirtazapine | Mirtazapine | 120 | 18 |
| Famotidine | Famotidine | 105 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 18 |
| Divalproex Sodium | Divalproex Sodium | 98 | 11 |
| Simvastatin | Simvastatin | 96 | 23 |
| Montelukast Sodium | Montelukast Sodium | 91 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 24 |
| Sucralfate | Sucralfate | 82 | suppressed |
| Levetiracetam | Levetiracetam | 79 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 27 |
| Allopurinol | Allopurinol | 75 | 16 |
| Memantine Hcl | Memantine Hcl | 74 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | suppressed |
| Myrbetriq | Mirabegron | 66 | suppressed |
| Gemfibrozil | Gemfibrozil | 65 | 18 |
| Diazepam | Diazepam | 64 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 24 |
| Brilinta | Ticagrelor | 62 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Prednisone | Prednisone | 61 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | suppressed |
| Spironolactone | Spironolactone | 60 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 42 |
| Lovastatin | Lovastatin | 58 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 17 |
| Methocarbamol | Methocarbamol | 56 | 16 |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Metformin Hcl Er | Metformin Hcl | 53 | 13 |
| Movantik | Naloxegol Oxalate | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Bumetanide | Bumetanide | 49 | 17 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Fluconazole | Fluconazole | 49 | 24 |
| Bupropion Xl | Bupropion Hcl | 47 | 11 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 11 |
| Glimepiride | Glimepiride | 46 | 13 |
| Clonidine Hcl | Clonidine Hcl | 45 | 20 |
| Promethazine Hcl | Promethazine Hcl | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Nystatin | Nystatin | 44 | 17 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 11 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 11 |
| Atenolol | Atenolol | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 30 |
| Valsartan | Valsartan | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Cephalexin | Cephalexin | 25 | 20 |
| Digoxin | Digoxin | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nyamyc | Nystatin | 22 | 17 |
| Topiramate | Topiramate | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 14 |
| Glyburide | Glyburide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 11 |
| Nateglinide | Nateglinide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Haloperidol Lactate | Haloperidol Lactate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.61 · 18 records | ViiV Healthcare Company | AIRSUPRA, Auvelity, CAPLYTA, MINIMED 780G, Ozempic, Rybelsus, VRAYLAR, VYEPTI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error